Výsledky vyhledávání

Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years

Autor: Christopher Barnowski, Miguel A. Escobar, Amy D. Shapiro, Doris Quon, Ateefa Chaudhury, Nisha Jain, Michael Wang, Elisa Tsao, Jing Feng

Publikováno v: Haemophilia

Introduction In clinical trials, recombinant factor IX fusion protein (rFIXFc) has demonstrated safety, efficacy and prolonged activity with extended dosing intervals for treatment of haemophilia B. Aim To assess the real-world clinical utility of rF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddd9057ec539136482a1183bffbca47b
http://europepmc.org/articles/PMC7821220

Zobrazit plný text záznamu

Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan

Autor: Toyomi Kamesaki, Jaime Morales, Hideho Wada, Elisa Tsao, Junichi Nishimura, Yuzuru Kanakura, Eric Yu

Publikováno v: International journal of hematology. 112(3)

Cold agglutinin disease (CAD) is a rare, complement-mediated autoimmune hemolytic anemia. Patients with CAD in the United States and Europe have an increased incidence of thromboembolism (TE), but comparable information for patients in other regions

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34f0408a103a6871e8e39033c8810884
https://pubmed.ncbi.nlm.nih.gov/32608010

Zobrazit plný text záznamu

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis

Autor: Steven W. Pipe, C. Druzgal, Mark Belletrutti, G. Miyasato, Sanjay P Ahuja, Courtney D. Thornburg, Amy D. Shapiro, Jennifer A. Dumont, Elisa Tsao, Nisha Jain, Janice M. Staber, J. Morales-Arias, Kenneth Lieuw, Nina Hwang, Manuel Carcao

Publikováno v: Haemophilia. 24:245-252

Introduction Immune tolerance induction (ITI) is the gold standard for eradication of factor VIII inhibitors in severe haemophilia A; however, it usually requires treatment for extended periods with associated high burden on patients and healthcare r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44e1f5d7d13910c56da11668e4f8b34d
https://doi.org/10.1111/hae.13413

Zobrazit plný text záznamu

Plný text ve formátu HTML

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

Autor: Victor S. Blanchette, Bent Winding, Johnny Mahlangu, Elisa Tsao, Roshni Kulkarni, Johannes Oldenburg, Jennifer A. Dumont, A. Srivastava, Nisha Jain

Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 24(1)

Introduction Joint arthropathy is the long-term consequence of joint bleeding in people with severe haemophilia. Aim This study assessed change in joint health over time in subjects receiving recombinant factor VIII Fc fusion protein (rFVIIIFc) proph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d845abc7d77566cfb9771973427e09f1
https://pubmed.ncbi.nlm.nih.gov/29082639

Zobrazit plný text záznamu

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A

Autor: Shuanglian Li, Johnny Mahlangu, Pratima Chowdary, Amy D. Shapiro, D. J. Perry, G. Allen, Doris Quon, Glenn F. Pierce, Elisa Tsao, Alison Innes, John Pasi

Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 23(3)

Introduction The Phase 3 A-LONG study demonstrated the safety and efficacy of rFVIIIFc for the control and prevention of bleeding episodes in severe haemophilia A. Aim To describe the treatment of bleeding episodes with rFVIIIFc in the A-LONG study.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ea001b4c0720c06541d0f8d8cbbfa02
https://pubmed.ncbi.nlm.nih.gov/28220631

Zobrazit plný text záznamu

Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure

Autor: Steven W. Pipe, Michael Wang, Sanjay P Ahuja, Nisha Jain, Hilda Ding, MacGregor Steele, Manuel Carcao, Jing Feng, Janice M. Staber, Haowei Linda Sun, Elisa Tsao, Zahra Al-Khateeb, Nina Hwang, Amy D. Shapiro, Kenneth Lieuw, Jennifer A. Dumont

Publikováno v: Blood. 132:2500-2500

Introduction: Immune tolerance induction (ITI) is the standard of care for eradication of inhibitors in subjects with severe hemophilia A. ITI is not always effective and can require a lengthy and burdensome treatment regimen. Those who have previous

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c63bae5849717f89092e8cb07663823
https://doi.org/10.1182/blood-2018-99-110467

Zobrazit plný text záznamu

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Children with Severe Hemophilia a

Autor: Bent Winding, Stefan Lethagen, K. John Pasi, Raina Liesner, Elisa Tsao, Guy Young, Lynda M. Cristiano, Beatrice Nolan, Johnny Mahlangu

Publikováno v: Blood. 128:1414-1414

Background: Factor VIII (FVIII) prophylaxis is the standard of care for patients with hemophilia A; however, conventional FVIII products usually require frequent intravenous infusions (3-4 times/week). The safety, efficacy, and prolonged half-life of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::683c59e73c943c44b26348f59cebcd0e
https://doi.org/10.1182/blood.v128.22.1414.1414

Zobrazit plný text záznamu

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a

Autor: K. John Pasi, David J. Perry, Hideji Hanabusa, Stefan Lethagen, Desilu Glazebrook, Lynda M. Cristiano, Ingrid Pabinger, Shannon Jackson, Bent Winding, Savita Rangarajan, Simon A Brown, Johnny Mahlangu, Elisa Tsao, Barbara A. Konkle

Publikováno v: Blood. 128:1413-1413

Background: Prophylactic replacement of coagulation factor VIII (FVIII) is the standard of care for patients with hemophilia A; however, prophylaxis with conventional FVIII products usually requires frequent intravenous injections (3-4 times/week). T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e3050a605378e099cd85aa0df560062
https://doi.org/10.1182/blood.v128.22.1413.1413

Zobrazit plný text záznamu

Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A

Autor: Bryce A. Kerlin, G. Allen, Michael Wang, Elisa Tsao, Beatrice Nolan, Hideji Hanabusa, Raina Liesner, Ingrid Pabinger-Fasching, Roshni Kulkarni, Simon A Brown, K. John Pasi

Publikováno v: Blood. 126:3520-3520

Background: The phase 3 A-LONG and Kids A-LONG studies demonstrated the safety and efficacy of recombinant FVIII Fc fusion protein (rFVIIIFc) for control and prevention of bleeding episodes in subjects with severe hemophilia A. The ongoing rFVIIIFc e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d53c966a23c2067275e316643193db0
https://doi.org/10.1182/blood.v126.23.3520.3520

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání